These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16611959)

  • 21. [Current status and prospects of chemotherapy of ovarian cancer].
    Sen K; Lang JH; Lian LJ
    Zhonghua Fu Chan Ke Za Zhi; 1994 Dec; 29(12):753-7. PubMed ID: 7712905
    [No Abstract]   [Full Text] [Related]  

  • 22. Chemotherapy of advanced ovarian cancer: current status and future directions.
    Ozols RF; Vermorken JB
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-1-S2-9. PubMed ID: 9045324
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Importance of delivered cycles and nomogram for intraperitoneal chemotherapy in ovarian cancer.
    Yen MS; Twu NF; Lai CR; Horng HC; Chao KC; Juang CM
    Gynecol Oncol; 2009 Sep; 114(3):415-9. PubMed ID: 19577277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment.
    Markman M; Walker JL
    J Clin Oncol; 2006 Feb; 24(6):988-94. PubMed ID: 16461779
    [No Abstract]   [Full Text] [Related]  

  • 25. Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look.
    Makhija S; Sabbatini P; Aghajanian C; Venkatraman E; Spriggs DR; Barakat R
    Gynecol Oncol; 2000 Oct; 79(1):28-32. PubMed ID: 11006026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer.
    Milczek T; Klasa-Mazurkiewicz D; Emerich J; Kobierski J
    Acta Obstet Gynecol Scand; 2009; 88(4):463-7. PubMed ID: 19235559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest.
    Gadducci A; Carnino F; Chiara S; Brunetti I; Tanganelli L; Romanini A; Bruzzone M; Conte PF
    Gynecol Oncol; 2000 Feb; 76(2):157-62. PubMed ID: 10637064
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Study by the Working Group in Gynecologic Oncology for therapeutic optimization in advanced FIGO IIb-IV ovarian carcinoma: cisplatin-paclitaxel vs. carboplatin-paclitaxel. AGO Protocol Ovar-3].
    Mettler L
    Zentralbl Gynakol; 1996; 118(6):379-4. PubMed ID: 8768017
    [No Abstract]   [Full Text] [Related]  

  • 29. Current status of chemotherapy for ovarian cancer.
    Ozols RF
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):61-6. PubMed ID: 7481863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study.
    Wenzel LB; Huang HQ; Armstrong DK; Walker JL; Cella D;
    J Clin Oncol; 2007 Feb; 25(4):437-43. PubMed ID: 17264340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Ovarian cancer treatment from the standpoint of the gynecologic oncologist].
    Sugiyama T; Yoshizaki A; Hatayama S
    Gan To Kagaku Ryoho; 2007 Jul; 34(7):1011-6. PubMed ID: 17637537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer.
    Bos AM; De Vos FY; de Vries EG; Beijnen JH; Rosing H; Mourits MJ; van der Zee AG; Gietema JA; Willemse PH
    Eur J Cancer; 2005 Mar; 41(4):539-48. PubMed ID: 15737558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vaginal evisceration during intraperitoneal chemotherapy for advanced ovarian cancer.
    Burkett AM; Cohn DE; Copeland LJ
    Gynecol Oncol; 2007 Feb; 104(2):491-3. PubMed ID: 17150244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemotherapy for ovarian cancer.
    Cvitkovic E; Misset JL
    N Engl J Med; 1996 May; 334(19):1269; author reply 1270. PubMed ID: 8606730
    [No Abstract]   [Full Text] [Related]  

  • 35. Intraperitoneal chemotherapy in ovarian carcinoma with the combination of carboplatin and 5-fluorouracil.
    Polyzos A; Giannikos L; Agrafiotis A; Kazaz M; Zonas C; Sfikakis P
    J Chemother; 1989 Jul; 1(4 Suppl):1220-1. PubMed ID: 16312842
    [No Abstract]   [Full Text] [Related]  

  • 36. Chemotherapy of advanced ovarian cancer.
    Martoni A; Cacciari N; Angelelli B; Zamagni C; Pannuti F
    Front Biosci; 1997 Mar; 2():g20-6. PubMed ID: 9159262
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intraperitoneal therapy for advanced ovarian cancer: will it become standard care?
    Bankhead C
    J Natl Cancer Inst; 2006 Apr; 98(8):510-2. PubMed ID: 16622116
    [No Abstract]   [Full Text] [Related]  

  • 38. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Bauknecht T; Warm M; Schroeder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of intraperitoneal chemotherapy in ovarian cancer.
    Markman M
    Clin Adv Hematol Oncol; 2006 Nov; 4(11):809-10. PubMed ID: 17143249
    [No Abstract]   [Full Text] [Related]  

  • 40. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.
    Walker JL; Armstrong DK; Huang HQ; Fowler J; Webster K; Burger RA; Clarke-Pearson D
    Gynecol Oncol; 2006 Jan; 100(1):27-32. PubMed ID: 16368440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.